UPLOAD Filing
REGENERON PHARMACEUTICALS, INC.
Date: April 17, 2025 · CIK: 0000872589 · Accession: 0000000000-25-004066
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19034
Letter
Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed February 5, 2025 File No. 000-19034 Dear Christopher Fenimore:
April 17, 2025
Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Richard Gluckselig
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 17, 2025 Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 Filed February 5, 2025 File No. 000-19034 Dear Christopher Fenimore: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Gluckselig </TEXT> </DOCUMENT>